OBJECTIVE: To evaluate a novel technique for on-line continuous glucose measurement in subcutaneous adipose tissue, and to investigate its accuracy for detection of hypoglycemia. RESEARCH DESIGN AND METHODS: The method combined an open-flow microperfusion of subcutaneous adipose tissue using a double lumen catheter and an extracorporeal sensor cell. An isotonic ion-free solution was perfused through the inner lumen of the catheter, equilibrated with the subcutaneous tissue fluid, and sampled through the outer lumen. The recovery was continuously monitored as the ratio between the measured sampled fluid conductivity and the subcutaneous tissue fluid conductivity (assumed to have a constant value of 1.28 S/m at 25 degrees C). Glucose concentration was calculated on-line from the measured glucose in the sampled fluid and the measured recovery in healthy volunteers during hyperglycemic glucose loads (n = 8), hypoglycemic hyperinsulinemic clamp (n = 6), and a 24-h monitoring period (n = 7). RESULTS: Subcutaneous glucose concentrations in the fasting state were 94% of the plasma glucose concentrations in arterialized venous samples. According to the error grid analysis, 96.9% of the on-line measured subcutaneous glucose concentrations during hyperglycemia and 96.3% during hypoglycemia were in accurate or acceptable zones. The mean differences between the measured subcutaneous glucose and the actual plasma glucose concentration were -0.06-3.3 mmol/l (hyperglycemia), and -0.6-1.1 mmol/l (hypoglycemia). CONCLUSIONS: By combining open-flow microperfusion, glucose sensor, and conductivity measurement, glucose concentration in the subcutaneous adipose tissue can be monitored on-line, extracorporeally, and continuously without any in vivo calibration, and gives accurate measurements during hyper- and hypoglycemia.
OBJECTIVE: To evaluate a novel technique for on-line continuous glucose measurement in subcutaneous adipose tissue, and to investigate its accuracy for detection of hypoglycemia. RESEARCH DESIGN AND METHODS: The method combined an open-flow microperfusion of subcutaneous adipose tissue using a double lumen catheter and an extracorporeal sensor cell. An isotonic ion-free solution was perfused through the inner lumen of the catheter, equilibrated with the subcutaneous tissue fluid, and sampled through the outer lumen. The recovery was continuously monitored as the ratio between the measured sampled fluid conductivity and the subcutaneous tissue fluid conductivity (assumed to have a constant value of 1.28 S/m at 25 degrees C). Glucose concentration was calculated on-line from the measured glucose in the sampled fluid and the measured recovery in healthy volunteers during hyperglycemic glucose loads (n = 8), hypoglycemic hyperinsulinemic clamp (n = 6), and a 24-h monitoring period (n = 7). RESULTS: Subcutaneous glucose concentrations in the fasting state were 94% of the plasma glucose concentrations in arterialized venous samples. According to the error grid analysis, 96.9% of the on-line measured subcutaneous glucose concentrations during hyperglycemia and 96.3% during hypoglycemia were in accurate or acceptable zones. The mean differences between the measured subcutaneous glucose and the actual plasma glucose concentration were -0.06-3.3 mmol/l (hyperglycemia), and -0.6-1.1 mmol/l (hypoglycemia). CONCLUSIONS: By combining open-flow microperfusion, glucose sensor, and conductivity measurement, glucose concentration in the subcutaneous adipose tissue can be monitored on-line, extracorporeally, and continuously without any in vivo calibration, and gives accurate measurements during hyper- and hypoglycemia.
Authors: Avraham Yacobi; Vinod P Shah; Edward D Bashaw; Eva Benfeldt; Barbara Davit; Derek Ganes; Tapash Ghosh; Isadore Kanfer; Gerald B Kasting; Lindsey Katz; Robert Lionberger; Guang Wei Lu; Howard I Maibach; Lynn K Pershing; Russell J Rackley; Andre Raw; Chinmay G Shukla; Kailas Thakker; Nathalie Wagner; Elizabeta Zovko; Majella E Lane Journal: Pharm Res Date: 2014-01-07 Impact factor: 4.200
Authors: Werner Regittnig; Stefan Lindpointner; Stefan Korsatko; Dina Tutkur; Manfred Bodenlenz; Thomas R Pieber Journal: Diabetes Technol Ther Date: 2012-11-05 Impact factor: 6.118
Authors: R Holmgaard; E Benfeldt; J B Nielsen; C Gatschelhofer; J A Sorensen; C Höfferer; M Bodenlenz; T R Pieber; F Sinner Journal: Pharm Res Date: 2012-03-15 Impact factor: 4.200
Authors: Roland Schaller; Franz Feichtner; Hans Köhler; Manfred Bodenlenz; Johannes Plank; Andrea Wutte; Julia K Mader; Martin Ellmerer; Reinhard Hainisch; Thomas R Pieber; Lukas Schaupp Journal: J Diabetes Sci Technol Date: 2009-01
Authors: Manfred Bodenlenz; Christian Dragatin; Lisa Liebenberger; Bernd Tschapeller; Beate Boulgaropoulos; Thomas Augustin; Reingard Raml; Christina Gatschelhofer; Nathalie Wagner; Khaled Benkali; Francois Rony; Thomas Pieber; Frank Sinner Journal: Pharm Res Date: 2016-06-06 Impact factor: 4.200
Authors: Martin Ellmerer; Martin Haluzik; Jan Blaha; Jaromir Kremen; Stepan Svacina; Andreas Plasnik; Dimas Ikeoka; Manfred Bodenlenz; Lukas Schaupp; Johannes Plank; Thomas R Pieber Journal: Int J Endocrinol Date: 2009-05-26 Impact factor: 3.257
Authors: Stefan Lindpointner; Stefan Korsatko; Gerd Köhler; Hans Köhler; Roland Schaller; Ruthy Kaidar; Ofer Yodfat; Lukas Schaupp; Martin Ellmerer; Thomas R Pieber; Werner Regittnig Journal: Diabetes Care Date: 2009-12-29 Impact factor: 17.152
Authors: Stefan Lindpointner; Stefan Korsatko; Gerd Köhler; Hans Köhler; Roland Schaller; Lukas Schaupp; Martin Ellmerer; Thomas R Pieber; Werner Regittnig Journal: Diabetes Care Date: 2010-01-22 Impact factor: 17.152